. The and . .. Endpoint,

. .. Study-treatments,

. Duration and . .. Treatment,

. Criteria, . Study, . Interruption, and . .. Discontinuation,

. Disease and . .. Criteria,

. End and . .. Study,

. Post and . .. Care,

. .. Biomarker-testing,

. .. Study-population,

. .. Inclusion-criteria,

. .. Study-assessments,


. .. Satmed-q, , p.61

. .. Post-treatment-assessments,

. .. Early-termination-assessments,

. End and . .. Study,

. Post and . .. Care,

. Adverse and . .. Management,

. 1definitions, A. Events, . Reactions, . Serious, and . Events-??????????????????????????????????????????64,

. .. Adverse-events,

A. Of, . Events, . Serious, and . .. Events,

. Assessment, . Causality, . Study, and . .. Procedures,

. Investigator, . Instructions, . Reporting, . Events, . Serious et al.,

. .. Adverse-events,


. .. Toxicity-management,

. Special and . .. Reports,

. Definitions, . Of, and . .. Situations,

D. C. Baumgart and W. J. Sandborn, Crohn's disease. s.l. : Lancet, vol.380, pp.1590-605, 2012.

, ALD n° 24 -Guide médecin sur la Maladie de Cohn et de la Rectocolite hémorragique. s.l. : Système national d'information inter-régimes de l'Assurance maladie (SNIIRAM) , Cartographie des patients et des dépenses, 2008.

N. A. Molodecky, I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris et al., Increasing incidenceand prevalence of the inflammatory bowel diseases with time, based on systematic review. s.l. : Gastroenterology, vol.142, pp.46-54, 2012.

G. Kaplan and S. Ng, Understanding and preventing the global incidence of Inflammatory Bowel Diseases. s.l. : Gastroenterology, vol.152, pp.313-321, 2017.

M. Olesen, C. Coskun, M. Peyrin-biroulet, L. Nielsen, and O. , Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. s.l. : Pharmacology & Therapeutics, vol.159, pp.110-119, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01664661

M. Van-der-have, K. S. Van-der-aalst, K. A. Leenders, M. Siersema, P. D. et al., Determinants of health-related quality of life in Crohn's disease: a systematic review and metaanalysis. s.l, J Crohns Colitis, vol.8, pp.93-106, 2014.

G. C. Parkes, K. Whelan, and J. O. Lindsay, Smoking in inflammatory bowel disease : impact on disease course and insights into the aetiology of its effect. s.l, J Crohns Colitis, vol.8, pp.717-742, 2014.

. Maunder, Evidence that stress contributes to inflammatory bowel disease: evalutaion, synthesis and future direction. s.l. : Inflamm Bowel Dis, vol.11, pp.600-608, 2005.

E. Lerebours, C. Gower-rousseau, and M. V. , Stressful life events as risk factor for inflammatory bowel disease onset: a population-based case-control study. s.l, Am J Gastroenterol, vol.102, pp.122-153, 2007.

A. Ahluwalia, L. Moraes, M. Magnusson, and L. Ohlman, Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. s.l, Scand J Gastroenterol, vol.53, pp.379-389, 2018.

A. Dignass, G. Van-assche, J. O. Lindsay, M. Lemann, J. Soderholm et al., The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. s.l. : Journal of Crohn's & colitis, vol.4, pp.28-62, 2010.

J. F. Colombel, N. Narula, and L. Peyrin-biroulet, Management strategies to improve outcomes in patients with Inflammatory Bowel diseases. s.l. : Gastroenterology, vol.152, pp.351-361, 2017.

J. F. Colombel, P. Rutgeerts, and W. Reinisch, Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. s.l. : Gastroenterology, vol.141, pp.1194-1201, 2011.

F. Baert, L. Moortgat, . Van-assche, and . Get, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. s.l. : Gastroenterology, vol.138, pp.463-471, 2010.

G. D'haens, F. Baert, . Van-assche, and . Get, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. s.l. : Lancet, vol.371, pp.660-667, 2008.

B. Ungar, I. Levy, Y. Yavne, M. Yavzori, O. Picard et al., Optimizing anti-TNF-a therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. s.l. : Clinical Gastroenterology and Hepatology, vol.14, pp.550-55, 2016.

F. D'amico, G. Fiorino, F. Furfaro, A. M. Danese, and S. , Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials, Expert Opinion on Investigational Drugs. s.l. : Expert Opinion on Investigational Drugs, vol.27, pp.595-599, 2019.

F. Macaluso, A. Orlando, and M. Cottone, Anti -interleukin-12 and anti-interleukin-23 agents in Crohn's disease. s.l. : Expert Opinion on Biological Therapy, vol.19, pp.89-98, 2019.

A. Gramlick, G. Fossati, and A. M. Nesbitt, Neutralization of soluble and membrane tumor necrosis factor (TNF) by infliximab, adalimumab, or certolizumab pegol using p55 or p75 TNF-receptorspecific bioassays. s.l. : Gastroenterology, vol.130, p.697, 2006.

J. Colombel, W. J. Sandborn, and P. Rutgeerts, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. s.l. : Gastroenterology, vol.132, pp.52-65, 2007.

L. Raffals, G. Nguyen, and T. Rubin, Switching between Biologics and Biosimilars in Inflammatory Bowel Disease. s.l. : Clinical Gastroenterology and Hepatology, vol.17, pp.818-823, 2019.

A. Al-sabbagh, E. Olech, J. E. Mcclellan, and C. F. Kirchhoff, evelopment of biosimilars. s.l. : Semin Arthritis Rheum, vol.45, pp.11-19, 2016.

, Expert Committee on Biological. Guidelines on evaluation of similar biotherapeutic products, 2009.

. Ebbers, Biosimilars: in support of extrapolation of indications. s.l, J Crohns Colitis, vol.8, issue.5, pp.431-436, 2014.

M. Weise, P. Kurki, E. Wolff-holz, M. C. Bielsky, and C. K. Schneider, Biosimilars: the science of extrapolation. s.l. : Blood, vol.124, pp.3191-3197, 2014.

A. , Developing oncology biosimilars: an essential approach for the future. s.l, J Semin Oncol, vol.1, issue.40, pp.5-24, 2013.

S. Danese, G. Fiorino, and T. Raine, ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. s.l. : J Crohn's Colitis, vol.11, pp.26-34, 2017.

K. K. Jorgensen, I. C. Olsen, and G. L. Goll, Switching from originatorinfliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. s.l. : Lancet, vol.389, pp.2304-2316, 2017.

C. P. Selinger, J. Eaden, and D. B. Jones, Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. s.l. : Inflamm Bowel Dis, vol.19, pp.2199-206, 2013.

S. Kane and F. Shaya, Medication non-adherence is associated with increased medical health care costs. s.l. : Dig Dis Sci, vol.53, pp.1020-1024, 2008.

S. V. Kane, J. Chao, and P. M. Mulani, Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. s.l. : Adv Ther, vol.26, pp.936-982, 2009.

L. Martelli, A. Lopez, S. Strobel, S. Danese, and X. Roblin, Adherence to infliximab therapy in inflammatory bowel disease patients in real-life setting. s.l, J Dig Dis, vol.10, pp.556-573, 2017.

L. Kristensen, R. Alten, L. Puig, S. Philipp, T. Kvien et al., Non-pharmacologicol effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. s.l. : BioGrugs, vol.32, pp.397-404, 2018.

. Rezk, To see or NOsee: the debate on the nocebo effect and optimizing the use of biosimilars. s.l, Adv Ther, vol.35, pp.749-753

L. Pouillon, M. Socha, B. Demore, N. Thilly, V. Abitbol et al., The nocebo effect: a clinical challenge in the era of biosimilars. s.l. : Expert Rev Clin Immunol, vol.14, pp.739-749, 2018.

R. Alten, J. Glover, and N. Matsunaga, Efficacy and safety results of a phase III study comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis. s.l. : Ann Rheum Dis, vol.76, p.59, 2017.

S. Cohen, M. C. Genovese, and E. Choy, Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, doubleblind, phase III equivalence study. s.l. : Ann Rheum Dis, vol.76, pp.1679-1687, 2017.

R. Ungaro, J. F. Colombel, T. Lissoos, and P. , A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. s.l, Am J Gastroenterol, vol.00, pp.1-10

M. Flamant and X. Roblin, Inflammatory Bowel disease: toward a personalized medicine. s.l. : Ther Adv Gastroenterol, vol.11, pp.1-15, 2018.

G. Fiorino, D. Gilardi, C. Correale, F. Furfaro, G. Roda et al., Biosimilars of adalimumab: the upcoming challenge in IBD. s.l. : Expert Opin Biol Ther, 2019.

J. Liu, T. Eris, and C. Li, Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. s.l. : BioDrugs, vol.30, pp.321-338, 2016.

K. Papp, H. Bachelez, and A. Costanzo, Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transititransition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. s.l, Br J Dermatol, vol.177, pp.1562-1574, 2017.

D. Shin, Y. Lee, and H. Kim, A randomized phase I comparativepharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. s.l, J Clin Pharm Ther, vol.42, issue.6, pp.672-678, 2017.

M. E. Weinblatt, A. Baranauskaite, and J. Niebrzydowski, Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. s.l. : Arthritis Rheumatol, vol.70, pp.40-48, 2018.

M. E. Weinblatt, A. Baranauskaite, and E. Dokoupilova, Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. s.l. : Arthritis Rheumatol, vol.70, pp.832-840, 2018.

V. Richter, O. Lemke, L. Haliduola, and H. , an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. s.l. : Expert Opin Biol Ther, pp.1-9, 2017.

A. Blauvelt, J. P. Lacour, and J. F. Fowler, Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. s.l, Br J Dermatol, vol.179, issue.3, pp.623-631, 2018.

. Al-salama, FKB327: An Adalimumab Biosimilar. s.l. : BioDrugs, 2019, pp.113-116

A. Puri, A. Niewiarowski, and A. Yasumasa, Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subject. s.l. : Br, J Clin Pharmacol, vol.83, pp.1405-1415, 2017.

C. Felice, D. Pugliese, and A. Armuzzi, The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases. s.l. : Expert Opin Biol Ther, 2019.

P. Biroulet, L. Danese, S. Cummings, A. Atreya, A. Greveson et al., Anti-TNF biosimilars in Crohn's disease: a patient-centric interdisciplinary approach. s.l. : Expert Rev Gastroenterol Hepatol, vol.13, pp.731-738, 2019.

L. Colloca and D. Finniss, Nocebo effects, patient-clinician communication, and therapeutic outcomes, JAMA, vol.307, pp.567-568, 2012.

L. Tweehuysen, V. Huiskes, . Van-den-bemt, . Bjf, . Vriezekolkje et al., Open-label nonmandatory transitioning from originator etanercept to biosimilar SB4: 6-month results from a controlled cohort study. s.l. : Arthritis Rheumatol, vol.70, pp.60-68, 2018.

L. Tweehuysen, V. Huiskes, B. Van-den-bemt, F. Van-den-hoogen, and A. A. Broeder, Higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy. s.l. : Ann Rheum Dis, vol.76, p.557, 2017.

L. Tweehuysen, B. Van-den-bemt, I. L. Van-ingen, A. De-jong, W. H. Van-der-laan et al., Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. s.l. : Arthritis Rheumatol, vol.70, pp.60-68, 2018.

L. Pouillon, S. Danese, A. Hart, G. Fiorino, M. Argollo et al., Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patient. s.l. : Aliment Pharmacol Ther, vol.49, pp.1181-1187, 2019.

E. Schmitz, B. Pj, and J. Straathof, Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. s.l. : Aliment Pharmacol Ther, vol.47, pp.356-363, 2018.

B. Nw, L. Liu, and R. Mj, The nocebo effect challenges the non-medical infliximab switch in practice. s.l, Eur J Clin Pharmacol, vol.74, pp.655-661, 2018.

L. Peyrin-biroulet, W. Sandborn, B. E. Sands, W. Reinisch, W. Bemelman et al., Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. s.l, Am J Gastroenterol, vol.110, pp.1324-1362, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01191653

C. Maaser, A. Sturm, S. R. Vavricka, T. Kucharzik, G. Fiorino et al.,

, European Crohn's and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology

. Ecco-esgar, Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complicat. s.l, J Crohns Colitis, vol.13, pp.144-164, 2019.

K. Faasse and K. J. Petrie, The nocebo effect: patient expectations and medication side effects. s.l, Postgrad Med J, vol.89, pp.540-546, 2013.

R. Horne and J. Weinman, Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. s.l, J Psychosom Res, vol.47, issue.6, pp.555-67, 1999.

. Sparrow, Adalimumab in ulcerative colitis-efficacy, safety and optimization in the era of treat-to target, vol.5, pp.613-621, 2017.

A. Sturm, C. Maaser, E. Calabrese, V. Annese, G. Fiorino et al.,

, European Crohn's and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology

. Ecco-esgar, Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. s.l, J Crohns Colitis, vol.13, issue.3, pp.273-284, 2019.

M. Ruiz, A. Pardo, J. Rejas, J. Soto, F. Villasante et al., Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). s.l. : Value Health, vol.11, pp.913-939, 2008.

S. Ghosh, E. Louis, L. Beaugerie, P. Bossuyt, G. Bouguen et al., Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. s.l. : Inflamm Bowel Dis, vol.23, pp.333-340, 2017.

W. Chan, A. Chen, D. Tiao, C. Selinger, and R. Leong, Medication adherence in inflammatory bowel disease. s.l. : Intest Res, vol.15, pp.434-445, 2017.

S. Delestras, M. Roustit, P. Bedouch, M. Minoves, V. Dobremez et al., Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. s.l. : PLoS One, vol.8, p.56247, 2013.

A. Hugon, M. Roustit, A. Lehmann, C. Saint-raymond, E. Borrel et al., Influence of intention to adhere, beliefs and satisfaction about medicines on adherence in solid organ transplant recipients. s.l. : Transplantation, vol.98, pp.222-230, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02007518